ATC kod: N03AD01
Det saknas kontrollerade studier om skillnader mellan könen avseende effekt och säkerhet för etosuximid. Kvinnor har lägre clearance än män, en skillnad som varierar i grad beroende på dos.
One study in patients treated with ethosuximide (20 boys/men, 26 girls/women; age 1.5-38 years) showed that plasma concentration increased more rapidly, relative to dose, in girls/women than in boys/men [1]. Another study in young adults (12 men, 21 women), with half of the women on oral contraceptives, revealed a 27% lower clearance in women in general and no difference associated with use of oral contraceptives [2]. No sex differentiation in dosing has been recommended by the pharmaceutical company [3].
No studies with a clinically relevant sex analysis regarding the effects of ethosuximide have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of ethosuximide have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Fler kvinnor än män hämtade ut oral lösning innehållande etosuximid (ATC-kod N03AD01) på recept i Sverige år 2019, totalt 393 flickor/kvinnor och 215 pojkar/män [4].
Uppdaterat: 2020-08-28
Litteratursökningsdatum: 2019-10-15
Faktagranskat av: Mia von Euler, Carl-Olav Stiller
Godkänt av: Karin Schenck-Gustafsson